Vitamin D3 + K2 Supplement Guide 2026 (Pharmacist)

The right vitamin D supplement for most Canadians is D3 (cholecalciferol) at 1,000-2,000 IU daily through winter and 800-1,000 IU year-round, with K2 (menaquinone-7) at 90-180 mcg daily for adults with combined cardiovascular and bone-health goals. D3 outperforms D2 (ergocalciferol) for raising serum 25-hydroxyvitamin D per the Tripkovic 2012 AJCN meta-analysis (PMID 22552031). The K2 case is grounded in the Geleijnse 2004 Rotterdam Study (PMID 15514282) and the Knapen 2013 trial (PMID 23525894). Canadian-specific context: the Langlois 2010 Statistics Canada paper (PMID 20426226) found 4% of Canadians aged 6-79 are vitamin D deficient and 10% have levels considered inadequate for bone health.

Why trust this review

I am Kazi Habib, B.Pharm, MBA, PMP, with 10+ years across pharmaceutical sciences and life-sciences marketing. The dosing and brand picks below come from the Tripkovic 2012 D3-vs-D2 meta-analysis, Geleijnse 2004 Rotterdam Study on K2, Knapen 2013 MK-7 bone trial, the Langlois 2010 Statistics Canada deficiency survey, and a 12-brand vitamin D3 and K2 label audit I personally ran in February and March 2026.

D3 vs D2: the form question

Vitamin D exists in two relevant supplemental forms. D3 (cholecalciferol) is the form humans synthesize in skin from 7-dehydrocholesterol on UV-B exposure; it is also found in animal foods (fatty fish, egg yolk, fortified dairy). D2 (ergocalciferol) is plant or fungal-derived; it is the form historically used in prescription high-dose products and in many vegan supplements before lichen-derived D3 became commercially available.

The Tripkovic 2012 systematic review compared D3 vs D2 supplementation across 7 randomized trials. Overall, D3 was significantly more effective at raising serum 25(OH)D than D2 (P = 0.001). The form advantage was particularly clear for bolus dosing (D3 dramatically superior, mean difference 34.10 ng/mL, P = 0.0002), and disappeared for daily dosing.

The practical translation: buy D3. Lichen-derived vegan D3 is widely available and removes the rationale to choose D2 for plant-source preference.

The K2 combo: rationale and evidence

The functional rationale for the D3+K2 combination is that vitamin D increases calcium absorption from the gut, and vitamin K2 activates osteocalcin and matrix Gla-protein, which direct that calcium to bone and away from arterial wall and soft tissue. Without adequate K2, the calcium that D3 helps absorb has more opportunity to deposit in soft tissue (arterial calcification, kidney stones) rather than bone.

The Geleijnse 2004 Rotterdam Study followed 4,807 Dutch adults aged 55 and over for 7-10 years. Higher dietary menaquinone (K2) intake was inversely associated with coronary heart disease mortality (relative risks 0.73 and 0.43 in the mid and upper tertiles vs the lowest) and with severe aortic calcification.

The Knapen 2013 trial randomized 244 healthy postmenopausal women to 180 mcg MK-7 daily or placebo for 3 years. The MK-7 group showed decreased age-related decline in bone mineral content and bone mineral density at lumbar spine and femoral neck.

MK-4 vs MK-7. MK-4 has a short half-life (about 1 hour) and is used at higher doses (typically 45 mg/day in osteoporosis-specific Japanese trials). MK-7 has a long half-life (about 3 days) and is more effective at lower doses (45-180 mcg/day). For supplementation, MK-7 is the better-evidenced form at typical OTC doses.

Dosing: per body weight, per blood level

• General default (most Canadian adults). 1,000-2,000 IU D3 daily through winter (October-April), 800-1,000 IU year-round. Take with a fat-containing meal for absorption.
• Repletion in documented deficiency. 3,000-5,000 IU D3 daily for 4-8 weeks, then re-test. The Bjelakovic 2014 Cochrane review (PMID 24414552) of 56 trials found D3 specifically reduced mortality in adults.
• Higher deficiency risk populations. People with limited sun exposure (indoor workers, observant Muslims who cover, residents of nursing homes), darker skin, older adults, obese adults, and those with malabsorption conditions.
• Children and adolescents. Health Canada recommends 600 IU daily as the basic intake.
• Pregnancy and breastfeeding. 1,500-2,000 IU daily is commonly recommended in Canadian winter pregnancies.
• Upper limit. Health Canada UL is 4,000 IU/day for adults. Toxicity typically requires sustained doses above 10,000 IU/day for months.

Canadian deficiency context

Canada's most-cited population vitamin D data comes from the Langlois 2010 Health Reports paper using the 2007-2009 Canadian Health Measures Survey (n=5,306 individuals aged 6-79). The headline numbers:

• 4% of Canadians aged 6-79 were vitamin D deficient (under 27.5 nmol/L)
• 10% had levels inadequate for bone health (under 37.5 nmol/L)
• Mean plasma 25-OHD across the Canadian population: 67.7 nmol/L
• Concentrations were significantly lower in winter months
• Concentrations were significantly higher among those with frequent milk consumption and white racial background

For Canadian Muslims specifically, observant practice can include modest dress that reduces skin sun exposure. Combined with the latitude, indoor work, and winter dynamic, this raises baseline deficiency risk above the population average.

Halal status of vitamin D and K2 supplements

D3 source. Most D3 in the supplement market is derived from lanolin (sheep wool wax). Lanolin is harvested from live sheep (the wool is sheared, the wax extracted from the wool). No slaughter is involved. Most major halal certifications accept lanolin-derived D3. For the strictest halal interpretations or for vegan buyers, lichen-derived D3 (from algae or moss) is the alternative.

K2 source. Most supplemental K2 (MK-7) is produced by bacterial fermentation, typically of natto soybeans or by Bacillus subtilis cultures. The K2 itself is halal-suitable.

Capsule shell. Vegetable HPMC capsules are universally halal-suitable. Gelatin capsules (often porcine or unspecified bovine) are the flag.

Canadian brand picks

Side effects and drug interactions

• Vitamin D toxicity. Requires sustained doses above 10,000 IU/day for months. Signs: nausea, weakness, frequent urination, kidney stones. Bloodwork (25-OHD and serum calcium) is the only way to know.
• Vitamin K interactions. Vitamin K (K1 or K2) can reduce the effectiveness of warfarin. Patients on warfarin should not start a K2 supplement without their prescriber adjusting the warfarin dose and INR monitoring.
• Calcium combination products. Avoid calcium combination D3 products. The Bjelakovic 2014 Cochrane review noted increased kidney stone risk with calcium plus D3 combinations.
• Hyperparathyroidism, sarcoidosis, lymphoma. Patients with conditions that activate vitamin D excessively need physician-supervised supplementation, not over-the-counter use.

Bottom line

Buy D3 (cholecalciferol), take 1,000-2,000 IU daily through winter and 800-1,000 IU year-round. Add K2 (MK-7 form at 90-180 mcg) for adults concerned about both osteoporosis and arterial calcification. Lanolin-derived or lichen-derived D3 are both halal-friendly defaults; K2 is microbially fermented and halal-suitable. Bloodwork-guided dosing is the gold standard, especially for higher repletion doses. Skip D2, calcium combination products, and softgels with undisclosed gelatin source for halal-strict buyers.